---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009706"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:10:58.026379+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences Q1 2022 net loss $12.8M; cash $133.3M; AU-011 pivotal trial in 2H 2022

## Summary
- Net loss of $12.8M in Q1 2022 compared to $5.9M in Q1 2021; cash and marketable securities $133.3M, sufficient into 2024.
- R&D expenses $8.3M (up from $4.2M) and G&A $4.5M (up from $1.7M), driven by manufacturing and public company costs.
- Plan to initiate pivotal trial for AU-011 in choroidal melanoma in 2H 2022; European Commission granted Orphan Drug Designation for uveal melanoma.
- IND submission for choroidal metastases and Phase 1 trial in NMIBC expected in 2H 2022, with initial data in 2023.
- Preclinical data at ASCO and AACR show AU-011's broad tumor targeting and combination potential with checkpoint inhibitors.

## SEC filing metadata
- accession: 0000950170-22-009706
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017022009706/0000950170-22-009706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017022009706/aura-20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009706
- JSON: https://secwatch.observer/filing/0000950170-22-009706.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.